Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05864053 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain

Study acronym: HNK
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Dec 2026 → Apr 2027
See other at-risk trials from Rush University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Primary completion pushed from Dec 2026 to Apr 2027
    • Study completion pushed from Dec 2026 to Aug 2027
    v8
  2. Minor Site contact updatedv7
  3. Minor Eligibility criteria revisedv6
  4. Minor Site contact updatedv5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2024 to Sep 19, 2024
    • Site details revised
    • Publications revised (52)
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Jun 2024 to Dec 2024v3
  2. Notable Start date: Jan 2024 to Jun 2024v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this randomized double blind three way (1:1:1) cross over clinical trial is to evaluate the effectiveness and duration of analgesia of a single infusion of (2R,6R)-HNK 0.5mg/kg compared with ketamine 0.5mg/kg and saline with a 5-week interval between treatments on pain, pain qualities, physical function, pain interference, sleep disturbance and quality of life in subjects with neuropathic pain of the extremities. The questions that this study will address are: 1. What is the analgesic efficacy of (2R,6R)-HNK on pain intensity and pain qualities in patients with chronic (\>3 month) neuropathic pain (NP). 2. What will be the effective duration of a single infusion of (2R,6R)-HNK in patients with NP. 3. Will (2R,6R)-HNK reduce pain related effects including interference in daily activities of life, sleep disturbances and change the qualities of pain reported by patients. Participants will receive each of the three study drugs in a random order at 5-week intervals over a 15 week period. The drug will be administered as a 45-minute infusion. Participants will complete quantitative sensory and pain evaluations and complete patient reported pain outcomes prior to receiving the first study drug and at 7, 14 and 21 and 35 days following study drug administration.
Trial Details
NCT Number NCT05864053
Lead Sponsor Rush University Medical Center
Collaborators: Congressionally Directed Medical Research Programs
Conditions
(from sponsor)
Pain, Neuropathic
Related terms Chronic Pain, Neuralgia, Pain
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov